Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Lilly, Incyte reel from FDA rejection
by Lisa M. Jarvis
April 24, 2017
| A version of this story appeared in
Volume 95, Issue 17
In a surprise move, FDA has rejected the arthritis treatment baricitinib, developed by Eli Lilly & Co. and Incyte. Shares of Lilly and Incyte were down 5% and 11%, respectively, on the first day of trading after the news was announced. In a response letter, FDA asked the companies for more clinical and safety data on baricitinib, a once-daily oral JAK inhibitor. The extra data could take the companies a year or more to supply, delaying the launch of what was anticipated to be a multi-billion-dollar-per-year drug.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X